Sympathetic block with botulinum toxin to treat complex regional pain syndrome
Ian Carroll, J David Clark, Sean Mackey, Ian Carroll, J David Clark, Sean Mackey
Abstract
Complex regional pain syndrome is a refractory pain condition with few tested therapies. We hypothesized that botulinum toxin A (BTA) would prolong analgesia after sympathetic blocks in patients with complex regional pain syndrome. We compared the duration of standard lumbar sympathetic block (LSB) with bupivacaine to LSB with bupivacaine and BTA in nine patients with refractory complex regional pain syndrome. Median time to analgesic failure was 71 (95% confidence interval, 12-253) days after LSB with BTA compared with fewer than 10 days (95% confidence interval, 0-12) after standard LSB (log-rank, p < 0.02). BTA profoundly prolonged the analgesia from sympathetic block in this preliminary study.
Conflict of interest statement
Potential conflict of interest: The authors report filing a patent for the use of botulinum toxins in sympathetic block.
Figures
Source: PubMed